Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 151

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children's Cancer Group and Japan Adult Leukemia Study Group

Blood (2024) 144 (Supplement 1): 1426.

https://doi.org/10.1182/blood-2024-199500

Published: 2024

Journal Articles

Prognostic Impact of Graft-Versus-Host Disease on Allogeneic Transplantation for CMML Focusing on Conditioning Intensity

Hidehiro Itonaga, Yasushi Miyazaki, Machiko Fujioka, Shuhei Kurosawa, Yasunobu Nagata, Yutaka Shimazu, Tomoaki Ueda, Naoyuki Uchida, Noriko Doki, Tetsuya Nishida, Ken-ichi Matsuoka, Masatsugu Tanaka, Makoto Yoshimitsu, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Takayoshi Tachibana

Blood (2024) 144 (Supplement 1): 6755.

https://doi.org/10.1182/blood-2024-193699

Published: 2024

Journal Articles

Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes

Rurika Okuda, Yotaro Ochi, Tetsuichi Yoshizato, Yasuhito Nannya, Yoshiko Atsuta, Yuichi Shiraishi, Yusuke Shiozawa, Hiroko Tanaka, Makoto Onizuka, Kenichi Chiba, Hidehiro Itonaga, Yoshinobu Kanda, Yasushi Miyazaki, Keizo Horibe, Satoru Miyano, Hideki Makishima, Seishi Ogawa

Blood (2024) 144 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2024-206498

Published: 2024

Journal Articles

JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults

Blood (2024) 144 (Supplement 1): 2819.

https://doi.org/10.1182/blood-2024-199435

Published: 2024

Journal Articles

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Blood (2024) 144 (Supplement 1): 1332.

https://doi.org/10.1182/blood-2024-194024

Published: 2024

Journal Articles

Optimal Procedures of Allogeneic Transplantation for BCR::ABL1 -Negative Atypical Chronic Myeloid Leukemia

Hidehiro Itonaga, Yasushi Miyazaki, Takeshi Kondo, Yutaka Shimazu, Jun Aoki, Shuhei Kurosawa, Takashi Ikeda, Tetsuya Eto, Naoyuki Uchida, Hideyuki Nakazawa, Koji Kawamura, Junya Kanda, Yoshiko Atsuta, Takayoshi Tachibana

Blood (2024) 144 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2024-193697

Published: 2024

Journal Articles

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2023-185857

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Amer M. Zeidan, Pierre Fenaux, Xia Han, David A. James, Kamel Malek, Pedro Marques Ramos, Yasushi Miyazaki, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2023-180765

Published: 2023

Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Blood (2023) 142 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2023-179252

Published: 2023

Journal Articles

Impact of Conditioning Intensity and Regimen on Outcomes after Unrelated Cord Blood Transplantation for Patients with Myelodysplastic Syndrome

Machiko Fujioka, Hidehiro Itonaga, Yasushi Miyazaki, Yoshimitsu Shimomura, Naoyuki Uchida, Satoshi Takahashi, Makoto Onizuka, Yasunori Ueda, Yasufumi Uehara, Masatsugu Tanaka, Yoshiko Matsuhashi, Shigesaburo Miyakoshi, Haruyuki Tanaka, Toshiro Kawakita, Fumihiko Ishimaru, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Ken Ishiyama

Blood (2023) 142 (Supplement 1): 3536.

https://doi.org/10.1182/blood-2023-179157

Published: 2023

Journal Articles

Prognostic Impact of Conditioning Intensity on Outcomes after Allogeneic Transplantation for MDS with Low Blasts

Hidehiro Itonaga, Yasushi Miyazaki, Machiko Fujioka, Ken Ishiyama, Jun Aoki, Noriko Doki, Tetsuya Nishida, Takahiro Fukuda, Naoyuki Uchida, Yasunori Ueda, Yasufumi Uehara, Yuta Katayama, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta

Blood (2023) 142 (Supplement 1): 4985.

https://doi.org/10.1182/blood-2023-173567

Published: 2023

Journal Articles

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki, Tohru Murayama, Takeshi Saito, Satoru Takada, Nobuaki Dobashi, Shuichi Ota, Yasuhisa Yokoyama, Masatsugu Tanaka, Shinya Sato, Shigeki Ohtake, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Itaru Matsumura, Yasushi Miyazaki, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2023-178332

Published: 2023

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 141 (5): 534–549.

https://doi.org/10.1182/blood.2022018221

Published: 2023

Includes: Supplemental data

Journal Articles

Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)

Valeria Santini, Uwe Platzbecker, Pierre Fenaux, Aristoteles Giagounidis, Yasushi Miyazaki, Mikkael A. Sekeres, Zhijian Xiao, Guillermo Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Pedro Marques Ramos, Amer M. Zeidan

Blood (2022) 140 (Supplement 1): 1340–1342.

https://doi.org/10.1182/blood-2022-160282

Published: 2022

Journal Articles

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Blood (2022) 140 (Supplement 1): 6902–6904.

https://doi.org/10.1182/blood-2022-168213

Published: 2022

Journal Articles

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Blood (2022) 140 (Supplement 1): 124–126.

https://doi.org/10.1182/blood-2022-156613

Published: 2022

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children's Cancer Group and Japan Adult Leukemia Study Group

Prognostic Impact of Graft-Versus-Host Disease on Allogeneic Transplantation for CMML Focusing on Conditioning Intensity

Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes

JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Optimal Procedures of Allogeneic Transplantation for BCR::ABL1 -Negative Atypical Chronic Myeloid Leukemia

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Impact of Conditioning Intensity and Regimen on Outcomes after Unrelated Cord Blood Transplantation for Patients with Myelodysplastic Syndrome

Prognostic Impact of Conditioning Intensity on Outcomes after Allogeneic Transplantation for MDS with Low Blasts

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only